Clozapine Treatment Protocol for Treatment-Resistant Schizophrenia

Defining Treatment Resistance

The American Psychiatric Association defines treatment resistance in schizophrenia as failure to respond to at least two adequate trials of different antipsychotics, with each trial lasting at least 6 weeks at therapeutic doses, and a minimum dose equivalent to 600mg chlorpromazine daily 1, 2, 3
Ideally, one trial should include a long-acting injectable antipsychotic to rule out non-adherence, as recommended by the American Psychiatric Association 2

The American Psychiatric Association recommends documenting target symptoms using standardized rating scales, such as the PANSS or BPRS, before initiating clozapine treatment 4

The American Psychiatric Association suggests measuring trough clozapine blood levels on at least two occasions separated by at least one week at stable dose, with a target blood level of ≥350 ng/ml to establish adequate trial 1, 5
If blood monitoring is not possible, a minimum dose of 500mg/day is recommended, unless limited by tolerability, as per the American Psychiatric Association guidelines 5
The American Psychiatric Association recommends continuing clozapine trial for at least 3 months after reaching therapeutic plasma levels before determining non-response 6

Response to clozapine is typically seen within 3 months of achieving therapeutic levels, as reported by the American Psychiatric Association 6

For patients who fail to respond to an adequate clozapine trial, the American Psychiatric Association recommends ensuring adequate clozapine blood levels (≥350 ng/ml) have been maintained, and considering augmentation strategies with a second antipsychotic or adjunctive treatments for specific symptom domains 1, 5, 4, 9

The American Academy of Child and Adolescent Psychiatry recommends long-term monitoring to reassess dosage needs based on illness phase, with higher doses required during acute phases and lower doses during residual phases 7, 8